Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Chemopreventive Agent Development
Sponsor
National Cancer Institute (NCI)
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT00896207
This randomized early phase I trial is studying different formulations of SR13668 in healthy volunteers. Giving SR13668 may help doctors learn more about how SR13668 is used by the body. It is not yet known which formulation of SR13668 is most effectively used by the body.
Intervention
Akt inhibitor SR13668
Condition
Healthy, no Evidence of Disease
Investigators
Paul Limburg